文献速递消化道肿瘤与早癌消化内镜

两样本粪便免疫化学检测筛查结直肠癌项目的检出率与有效性

Yield and Effectiveness of 2-Sample Fecal Immunochemical Test-Based Screening Program for Colorectal Cancer.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-11-06

在中国人群中评估两样本粪便免疫化学检测(FIT)筛查结直肠癌的检出率与有效性。246,349名受邀者中150,524人(61.10%)参与,16,994人(11.29%)FIT阳性,其中12,816人(75.41%)接受结肠镜。中位随访10.58年,FIT阳性且接受结肠镜者结直肠癌发病风险与FIT阴性者相似(HR 0.94),但死亡风险较高(HR 1.62);未接受结肠镜者发病和死亡风险均更高。

要点

  • 两样本FIT筛查参与率61.10%,阳性者中75.41%接受结肠镜。
  • FIT阳性且接受结肠镜者结直肠癌发病风险与FIT阴性者相似(HR 0.94)。
  • FIT阳性未接受结肠镜者结直肠癌发病和死亡风险显著增高(HR 3.52和4.41)。

核心结论

  • 两样本FIT可有效识别高危人群,结肠镜依从性与较低的结直肠癌发病和死亡风险相关。

研究设计与样本

  • 2007年至2021年邀请符合条件个体参与两样本FIT筛查,阳性者(2013年前 cutoff 40 μg/g,之后20 μg/g)转诊结肠镜。
  • 共246,349名受邀者,150,524人(61.10%)参与两样本FIT,16,994人(11.29%)FIT阳性。
  • 参与者分为FIT阳性且接受结肠镜组、FIT阳性未接受结肠镜组和FIT阴性对照组,比较结直肠癌发病和死亡风险。

主要发现

  • FIT阳性者中12,816人(75.41%)接受结肠镜,进展期肿瘤检出率为0.57%,阳性预测值为6.70%。
  • 中位随访10.58年。
  • 与FIT阴性参与者相比,FIT阳性且接受结肠镜者结直肠癌发病风险相似(HR 0.94,95%CI 0.75-1.19),死亡风险较高(HR 1.62,95%CI 1.09-2.41)。
  • 与FIT阴性参与者相比,FIT阳性未接受结肠镜者结直肠癌发病风险更高(HR 3.52,95%CI 2.85-4.34),死亡风险更高(HR 4.41,95%CI 2.96-6.55)。
  • 以50.0岁时FIT阴性参与者的结直肠癌发病和死亡风险为基准,FIT阳性且接受结肠镜者达到相同风险的年龄分别为50.6岁和46.1岁,未接受结肠镜者分别为38.0岁和37.9岁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Colorectal cancer (CRC) incidence and mortality of China account for nearly 30% of the global attributable fraction. We aimed to estimate the yield and effectiveness of a 2-sample fecal immunochemical test (FIT)-based screening program in China. METHODS: Eligible individuals were invited for 2-sample FIT between 2007 and 2021, with positive ones (cutoff 40 μg/g before 2013 and 20 μg/g thereafter) referred for colonoscopy. Participation rates, detection rates, and positive predictive values were calculated. Participants were classified into: FIT+/colonoscopy compliers, FIT+/colonoscopy noncompliers, and FIT- as control subjects. We compared CRC incidence and mortality and calculated the age reaching comparable risk. RESULTS: Among 246,349 invitees, 150,524 (61.10%) participated in 2-sample FIT, with 16,994 (11.29%) identified as FIT+; 12,816 (75.41%) underwent colonoscopy, yielding a detection rate and positive predictive value of 0.57% and 6.70% for advanced neoplasia, respectively. Median follow-up was 10.58 years. Compared with FIT- participants, CRC incidence and mortality were relatively similar among FIT+/colonoscopy compliers with hazard ratios of 0.94 (95% confidence interval [CI], 0.75-1.19) and 1.62 (95% CI, 1.09 to 2.41) but higher among noncompliers, with hazard ratios of 3.52 (95% CI, 2.85-4.34) and 4.41 (95% CI, 2.96-6.55). Taking CRC incidence and mortality risk of FIT- participants at 50.0 years of age as the benchmark, FIT+/colonoscopy compliers reached same risk at 50.6 and 46.1 years of age, while noncompliers reached the same risk at 38.0 and 37.9 years of age, respectively. CONCLUSIONS: Two-sample FIT could effectively identify high-risk populations, and colonoscopy compliance is associated with a lower risk of CRC incidence and mortality. This strategy might facilitate CRC screening practice in countries with large populations.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Xu Z, Yang J, He J, et al. Yield and Effectiveness of 2-Sample Fecal Immunochemical Test-Based Screening Program for Colorectal Cancer. Clin Gastroenterol Hepatol. 2024. PMID: 39510222. doi:10.1016/j.cgh.2024.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。